| NCT02693535 | II | Ovarian expansion for BRCA1/2 MUT, or CDKN2A loss or MUT, or high TMB, or ERBB2 AMP, MUT or over-expression or Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, FGFR1-3, FLT-3, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMB | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | AL, AZ, CA, FL, GA, HI, IL, IN, ME, MI, NE, NH, NC, ND, OK, OR, PA, SD, TX, UT, VA, WA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Afatinib | BIBW 2992 MA2, Gilotrif, Afatinib dimaleate | EGFR, HER2, HER4 kinase inhibitor | Approved in Other Cancers | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Temsirolimus | Torisel, CCI-779 | mTOR inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Vemurafenib | RO5185426, PLX4032, Zelboraf | BRAF kinase inhibitor | Approved in Other Cancers |
|
|
| NCT02873962 | II | Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor) | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04123366 | II | Advanced BRCA WT solid tumors with mutations in homologous repair (HRR) genes (i.e. BRIP1, PALB2) or HRD+ patients, no prior PARP inhibitor or checkpoint inhibitor | A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer | AL, AZ, CA, CO, FL, GA, KY, NJ, NY, OH, OK, TX, UT, VA, WA | View Drugs | View Results |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
Cediranib | AZD2171, Cediranib maleate, Recentin | VEGFR1-3 kinase inhibitor | Clinical Trials | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02953457 | I/II | Recurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or dMMR, HRR gene alterations or LOH high score | A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation | NY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT04673448 | I | Recurrent BRCA MUT ovarian cancer | Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer | WA | View Drugs | View Results |
Dostarlimab | ANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|